ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

ATHA Athira Pharma Inc

2,04
0,00 (0,00%)
Vor Marktöffnung
Zuletzt aktualisiert: 10:00:00
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Athira Pharma Inc ATHA NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,00 0,00% 2,04 10:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
2,04
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
15.4.202413:00GLOBEAthira Pharma Appoints Javier San Martin, M.D., as Chief..
11.4.202413:00GLOBEAthira Pharma Announces Publication of Preclinical Data..
03.4.202413:00GLOBEAthira Pharma Announces Upcoming Poster Presentation at..
08.3.202413:00GLOBEAthira Pharma Presents Clinical and Preclinical Data..
22.2.202422:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
22.2.202422:10EDGAR2Form 8-K - Current report
22.2.202422:05GLOBEAthira Pharma Reports Full Year 2023 Financial Results and..
16.2.202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202422:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202422:40EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
08.2.202422:02GLOBEAthira Pharma Announces Publication in Frontiers in..
08.1.202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.1.202422:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.1.202422:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.1.202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.1.202413:11EDGAR2Form 8-K - Current report
08.1.202413:00GLOBEAthira Pharma Provides 2024 Clinical Pipeline Outlook and..
03.1.202413:00GLOBEAthira Pharma Completes Enrollment of Phase 2/3 LIFT-AD..
12.12.202313:00GLOBEAthira Pharma Announces Encouraging Results from SHAPE Phase..
29.11.202313:00GLOBEAthira Pharma to Participate in Sidoti December Small Cap..
28.11.202313:00GLOBEAthira Pharma Announces Upcoming Presentation at Motor..
15.11.202314:15GLOBEAthira Pharma Presents Preclinical Data Highlighting..
09.11.202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.11.202322:10EDGAR2Form 8-K - Current report
09.11.202322:05GLOBEAthira Pharma Reports Third Quarter 2023 Financial Results..
08.11.202313:00GLOBEAthira Pharma to Participate in Jefferies London Healthcare..
05.10.202322:30GLOBEAthira Pharma Presents Preclinical Data Further Supporting..
28.9.202313:00GLOBEAthira Pharma to Participate in Upcoming October Conferences
19.9.202313:00GLOBEAthira Pharma to Participate in the 2023 Cantor Fitzgerald..
10.8.202322:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10.8.202322:10EDGAR2Form 8-K - Current report
10.8.202322:05GLOBEAthira Pharma Reports Second Quarter 2023 Financial Results..
17.7.202313:00GLOBEAthira Pharma Presents Phase 2 Clinical Data Correlating..
06.7.202313:00GLOBEAthira Pharma Announces Upcoming Presentations at the..
31.5.202313:00GLOBEAthira Pharma to Participate in Upcoming June Conferences
22.5.202313:00GLOBEAthira Pharma Appoints Andrew Gengos as Chief Financial..
11.5.202322:05GLOBEAthira Pharma Reports First Quarter 2023 Financial Results..
08.5.202313:00GLOBEAthira Pharma to Participate in Upcoming May Investor..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock